Provided by Tiger Trade Technology Pte. Ltd.

AKESO

93.600
-1.450-1.53%
Volume:7.15M
Turnover:672.65M
Market Cap:86.21B
PE:-65.01
High:96.000
Open:95.050
Low:93.400
Close:95.050
52wk High:156.000
52wk Low:80.200
Shares:921.00M
HK Float Shares:921.00M
Volume Ratio:0.46
T/O Rate:0.78%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-1.440
ROE:-13.59%
ROA:-4.57%
PB:8.70
PE(LYR):-65.01
PS:21.39

Loading ...

Innovative Drug Sector Surges, Leading Market Rebound with Key ETFs and Stocks Soaring

Deep News
·
Jun 29

Movement Alert|Akeso Bio Rises 3.66% in Regular Trading, Ivonescimab Tops Evaluate Global Most Valuable Pipeline Ranking

Market Focus
·
Jun 29

Movement Alert|Akeso Falls 3.16% in Regular Trading, Post-ASCO Profit-Taking Continues as Stock Nears 52-Week Low

Market Focus
·
Jun 26

Movement Alert|Akeso Falls 3.43% in Regular Trading, Post-ASCO Profit-Taking Persists as Biotech Sector Weakens Again

Market Focus
·
Jun 25

Movement Alert|Akeso Rises 3.1% in Regular Trading, Multiple Brokerages Issue Buy Ratings Amid Biotech Sector Rebound

Market Focus
·
Jun 24

Hong Kong Stocks Surge: Innovative Drug Sector Rallies on Regulatory Report and New Foreign Investment Policies

Stock News
·
Jun 23

China Securities Research Initiates Coverage on AKESO with a "Buy" Rating, Citing Multiple Growth Drivers

Stock News
·
Jun 23

Movement Alert|Akeso Rises 3.44% in Regular Trading, Buyback Support and Broker Buy Rating Trigger Rebound Near 52-Week Low

Market Focus
·
Jun 23

Movement Alert|Akeso Inc Falls 3.88% in Regular Trading, Sustained Selling Pressure Post-ASCO Data as Buyback Fails to Reverse Trend

Market Focus
·
Jun 22

Akeso (SEHK:9926) Stock Could Be 49% Undervalued After New AML Trial Data

Simply Wall St.
·
Jun 19

Movement Alert|Akeso Rises 3.64% in Regular Trading, Industry Buyback Wave and Sector Oversold Rebound Support Price Stabilization

Market Focus
·
Jun 18

Akeso says Phase II trial shows ligufalimab plus azacitidine, venetoclax extends event-free survival in frontline AML

Reuters
·
Jun 17

Movement Alert|Akeso Falls 3.41% in Regular Trading, Buyback Plan Fails to Halt Post-ASCO Profit-Taking Pressure

Market Focus
·
Jun 16

Akeso enrolls first patient in Phase Ib/II study of HER3 ADC AK138D1 plus ivonescimab in advanced breast cancer

Reuters
·
Jun 15

Akeso's Next-Generation Her3 ADC Ak138d1 Combined With Ivonescimab: First Patient Enrolled in Phase Ib/Ii Breast Cancer Study, Advancing the IO2.0 + ADC2.0 Strategy

THOMSON REUTERS
·
Jun 15

Movement Alert|Akeso Bio Falls 3.04% in Regular Trading, Post-ASCO Selling Pressure Resumes After Brief Buyback-Driven Rebound

Market Focus
·
Jun 15

AKESO's Novel Drug AK111 Receives Marketing Authorization from Chinese Regulators for Plaque Psoriasis

Stock News
·
Jun 12

Akeso - Nmpa Approves New Drug Application for Gumokimab (Ak111)

THOMSON REUTERS
·
Jun 12

Movement Alert|Akeso Bio Rises 3.13% in Regular Trading, Board Approves HK$200 Million Buyback Plan and Management Pledges HK$50 Million in Open-Market Purchases

Market Focus
·
Jun 12

Akeso says China NMPA approves gumokimab for moderate-to-severe plaque psoriasis

Reuters
·
Jun 12